Midregional pro atrial naturetic peptide (MRproANP) is a predictor of all-cause mortality in mild to moderate COPD - an analysis of COSYCONET data
<bold>Background:</bold> When chronic obstructive pulmonary disease (COPD) is newly diagnosed in the mild to moderate stages (Global Initiative for chronic obstructive Lung Disease [GOLD] stage 0-2), it is difficult to identify patients at increased risk of death. <bold>Methods:</bold> Therefore, we examined the prediction of mortality by the biomarkers Copeptin (COPAVP), midregional adrenomedullin (MRproADM), pro atrial naturetic peptide (MRproANP), and Fibrinogen in subjects with stable COPD GOLD 0-4 and GOLD 0-2 (diagnosis COPD for less than 5 years) of the COSYCONET cohort (COPD and Systemic Consequences - Comorbidities Network). <bold>Results:</bold> 235 subjects of 2253 subjects with stable COPD 0-4 and 43 subjects of 655 with GOLD 0-2 (diagnosed less than 5 years ago) died during the 6-year follow-up period. In both groups, Cox regression after adjusting for confounding factors (COPD characteristics, other risk factors, cardiovascular disease, log10troponine, and creatinine) revealed that the fourth quartile of MRproANP is a robust biomarker of all-cause mortality. <bold>Conclusion:</bold> In contrast to the biomarkers COPAVP, MRproADM and Fibrinogen, the fourth quartile of MRproANP is a robust biomarker of all-cause mortality even in subjects with early stages of COPD and a recently diagnosed COPD.
Authors
- Daiana Stolz (ORCID: https://orcid.org/0000-0003-0099-882X)
- Sebastian Teuteberg
- Frederik Seiler
- Hans‐Ulrich Kauczor (ORCID: https://orcid.org/0000-0002-6730-9462)
- Peter J. Alter (ORCID: https://orcid.org/0000-0002-2115-1743)
- Rudolf A. Jörres (ORCID: https://orcid.org/0000-0002-9782-1117)
- Isabelle Moneke (ORCID: https://orcid.org/0000-0002-1019-5214)
- Frank Biertz (ORCID: https://orcid.org/0000-0003-0686-6123)
- Tanja Zeller (ORCID: https://orcid.org/0000-0003-3379-2641)
- Robert Bals (ORCID: https://orcid.org/0000-0002-1472-9535)
- Benjamin Waschki (ORCID: https://orcid.org/0000-0002-1070-3661)
- Johanna Classen
- Claus Franz Vogelmeier (ORCID: https://orcid.org/0000-0002-9798-2527)
- Tobias Welte (ORCID: https://orcid.org/0000-0002-9947-7356)
- Kathrin Kahnert (ORCID: https://orcid.org/0000-0001-9633-3368)
- Christian Herr (ORCID: https://orcid.org/0000-0001-9422-6569)
- Sebastian Fähndrich (ORCID: https://orcid.org/0000-0002-2277-2672)
- Albert Omlor (ORCID: https://orcid.org/0000-0002-0030-9468)
- Franziska Christina Trudzinski (ORCID: https://orcid.org/0000-0002-0980-7586)
- Martin Eichenlaub (ORCID: https://orcid.org/0000-0003-3674-790X)
- Henrik Watz
- Sandra Söhler (ORCID: https://orcid.org/0000-0001-5851-1872)
- Victoria Weinhold
- J Michels-Zetsche
- Julia Adams
- Daniel Bross Soriano
Institutions
- Universität Hamburg (DE)
- Philipps University of Marburg (DE)
- Heidelberg University (DE)
- University Medical Center Freiburg (DE)
- University Hospital Heidelberg (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Itzehoe (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- German Center for Lung Research (DE)
- LungenClinic Grosshansdorf (DE)
- Ludwig-Maximilians-Universität München (DE)
- Saarland University (DE)
Publication Details
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1183/13993003.congress-2024.pa3973
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00